Amneal Biosciences received approval for its Triamcinolone Acetonide Injectable Suspension, USP in 40 mg/mL dosage strength. The product will be sold in 1 mL single-dose vials as well as in 5 mL and 10 mL multiple dose vials. Amneal's triamcinolone acetonide will be the only AP-rated generic equivalent injectable suspension available.
"This important launch demonstrates the depth of our ability to successfully develop and manufacture complex products in our state-of-the-art manufacturing facilities," notes Chirag Patel, Co-CEO and co-Chairman for Amneal Pharmaceuticals.
Annual U.S. sales of Kenalog-40 injection were $146 million according to October 2017 IQVIA market data. Triamcinolone acetonide injectable suspension will be available direct and through wholesalers and distributors.